AbbVie
AbbVie's Elahere Approved in Europe for FRα-Positive Ovarian Cancer
Elahere's companion diagnostic, Roche's Ventana FOLR1 (FOLR1-2.1) RxDx assay, also garnered CE marking.
AbbVie to Buy Aliada Therapeutics for $1.4B in Cash
Through the acquisition, AbbVie will gain Aliada's lead asset, a beta-amyloid-targeting drug in a Phase I trial designed to cross the blood-brain barrier.
AbbVie's Telisotuzumab Vedotin Effective in NSCLC Patients With High, Intermediate c-MET Expression
Premium
The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.
The firms expect to seek regulatory approval for a subretinal version of the therapy in 2026 though they are also developing a suprachoroidal formulation.
ImmunoGen Achieves Full FDA Approval for Elahere in Folate Receptor Alpha-Positive Ovarian Cancer
The agency made the decision after reviewing results from the confirmatory Phase III MIRASOL clinical trial.